Brief: Ikena Oncology Reports Fourth Quarter And Full Year 2022 Financial Results
14/03/2023 11:14
March 14 (Reuters) - Ikena Oncology Inc IKNA.O :
* IKENA ONCOLOGY REPORTS FOURTH QUARTER AND FULL YEAR 2022
FINANCIAL RESULTS
* IKENA ONCOLOGY INC - FOCUSED TARGETED ONCOLOGY PIPELINE
ADVANCING TOWARDS MULTIPLE NEAR-TERM MILESTONES; RUNWAY INTO
2025
* IKENA ONCOLOGY INC- QTRLY LOSS PER SHARE $0.39
Source text for Eikon: ID:nGNX5RFH6L
Further company coverage: IKNA.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on ImageneBio
See all newsU.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma
Brief: ImageneBio Inc - On Oct 23, Elects Not To Renew Agreement With Miragene - SEC Filing
ImageneBio Inc expected to post a loss of $1.56 a share - Earnings Preview
Brief: Ikena Oncology Announces Stockholder Approval Of Merger With Inmagene Biopharmaceuticals